com_NN
Health_NN
problems_NN
related_VBN [WZPAST]
to_PIN
the_DT
function_NOMZ
Key_NN
product_NN
sales_NN
:_:
Cardiovascular_NN
With_PIN
its_PIT
novel_NN
mode_NN
of_PIN
action_NOMZ
,_,
Faslodex_NN
2004_CD
2003_CD
Underlying_GER
of_PIN
the_DT
central_JJ
nervous_JJ
system_NN
,_,
including_VBG
offers_NN
an_DT
effective_JJ
,_,
well-tolerated_JJ
additional_JJ
$_$
m_CD
$_$
m_JJ
growth_NN
%_NN
the_DT
brain_NN
,_,
are_VPRT [BEMA]
a_DT
complex_JJ
area_NN
of_PIN
significant_JJ
breast_NN
cancer_NN
therapy_NN
,_,
in_PIN
a_DT
convenient_JJ
Seloken_NN
1,387_CD
1,280_CD
6_CD
medical_JJ
need_NN
._.
Following_VBG
EU_NN
Crestor_NN
908_CD
129_CD
n_NN
m_NN
approval_NN
in_PIN
March_NN
2004_CD
,_,
Faslodex_NN
is_VPRT
Atacand_NN
879_CD
750_CD
10_CD
In_PIN
September_NN
2004_CD
,_,
Seroquel_NN
became_VBD
now_TIME
available_JJ
in_PIN
Europe_NN
as_RB
well_RB
as_IN
the_DT
Plendil_NN
455_CD
540_CD
20_CD
the_DT
market_NN
leading_VBG [WZPRES]
atypical_JJ
anti-psychotic_JJ
US_FPP1
,_,
Brazil_NN
and_PHC
Argentina_NN
for_PIN
the_DT
Zestril_NN
440_CD
478_CD
15_CD
in_PIN
the_DT
US_FPP1
in_PIN
terms_NN
of_PIN
monthly_JJ
new_JJ
treatment_NOMZ
of_PIN
advanced_JJ
breast_NN
cancer_NN
Tenormin_NN
368_CD
342_CD
prescriptions_NOMZ
._.
In_PIN
Europe_NN
,_,
Seroquel_NN
is_VPRT [BEMA]
in_PIN
post-menopausal_JJ
women_NN
._.
Other_JJ
340_CD
391_CD
20_CD
growing_VBG
two_CD
to_PIN
three_CD
times_NN
faster_JJ
than_PIN
the_DT
Total_JJ
4,777_CD
3,910_CD
17_CD
atypical_JJ
market_NN
,_,
with_PIN
excellent_JJ
market_NN
Sales_NN
of_PIN
Casodex_NN
and_PHC
Arimidex_NN
,_,
for_PIN
treating_VBG
share_NN
gains_NN
,_,
notably_RB
in_PIN
Italy_NN
and_PHC
Germany_NN
._.
prostate_NN
and_PHC
breast_NN
cancer_NN
respectively_RB
,_,
Key_NN
product_NN
sales_NN
:_:
Gastrointestinal_JJ
showed_VBD [PRIV]
continued_VBN
good_JJ
growth_NN
._.
Further_JJ
2004_CD
2003_CD
Underlying_JJ
$_$
m_CD
$_$
m_JJ
growth_NN
%_NN
The_DT
launch_NN
of_PIN
Seroquel_NN
in_PIN
the_DT
US_FPP1
and_CC
large-scale_JJ
clinical_JJ
study_NN
data_NN
presented_VBN [WZPAST]
in_PIN
Nexium_NN
3,883_CD
3,302_CD
15_CD
Europe_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
bipolar_NN
mania_NN
December_NN
2004_CD
showed_VBD [PRIV]
that_THVC
Arimidex_NN
is_VPRT
Losec_NN
Prilosec_NN
1,947_CD
2,565_CD
30_CD
which_WDT
affects_VPRT
over_IN
17_CD
million_CD
people_NN
in_PIN
the_DT
significantly_RB
more_EMPH
effective_JJ
than_PIN
tamoxifen_JJ
Other_JJ
88_CD
76_CD
9_CD
major_JJ
markets_NN
has_VPRT [PEAS]
been_VBN [BEMA]
very_AMP
successful_PRED
,_,
in_PIN
prolonging_VBG
disease-free_JJ
survival_NN
._.
The_DT
Total_JJ
5,918_CD
5,943_CD
4_CD
with_PIN
strong_JJ
market_NN
share_NN
growth_NN
._.
same_JJ
study_NN
also_RB
showed_VBD [PRIV]
that_THVC
women_NN
switching_VBG [WZPRES]
from_PIN
tamoxifen_NN
to_PIN
Arimidex_NN
Key_NN
product_NN
sales_NN
:_:
Infection_NOMZ
Following_VBG [WZPRES]
successful_JJ
launches_NN
in_PIN
the_DT
US_FPP1
suffer_VPRT
fewer_JJ
recurrences_NN
of_PIN
their_TPP3
early_TIME
2004_CD
2003_CD
Underlying_JJ
and_CC
Europe_NN
of_PIN
Zomig_NN
Nasal_NN
Spray_NN
,_,
a_DT
new_JJ
breast_NN
cancer_NN
than_PIN
those_DEMP
who_WP
stay_VPRT
on_PIN
$_$
m_CD
$_$
m_JJ
growth_NN
%_NN
formulation_NOMZ
of_PIN
our_FPP1
Zomig_NN
migraine_NN
therapy_NN
tamoxifen_NN
through_PIN
the_DT
standard_JJ
five-year_JJ
Merrem_NN
423_CD
346_CD
15_CD
in_PIN
a_DT
convenient_JJ
device_NN
that_TSUB
delivers_VPRT
fast_RB
course_NN
of_PIN
treatment_NOMZ
._.
Other_JJ
116_CD
130_CD
16_CD
pain_NN
relief_NN
,_,
we_FPP1
anticipate_VPRT [PRIV]
launch_NN
in_PIN
Japan_NN
Total_NN
539_CD
476_CD
7_CD
in_PIN
2005_CD
._.
Respiratory_NN
and_PHC
Inflammation_NOMZ
Already_RB
a_DT
leader_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
asthma_NN
,_,
Key_NN
product_NN
sales_NN
:_:
Neuroscience_NN
Our_FPP1
leading_VBG
range_NN
of_PIN
anaesthetics_NN
continued_VBD
we_FPP1
plan_VPRT
to_TO
expand_VB
our_FPP1
range_NN
through_PIN
the_DT
2004_CD
2003_CD
Underlying_JJ
$_$
m_CD
$_$
m_JJ
growth_NN
%_NN
to_TO
perform_VB
well_RB
._.
Anaesthesia_NN
sales_NN
introduction_NOMZ
of_PIN
new_JJ
uses_NN
for_PIN
our_FPP1
key_JJ
Seroquel_NN
2,027_CD
1,487_CD
33_CD
exceeded_VBD
$_$
1_CD
billion_CD
in_PIN
2004_CD
including_VBG
$_$
500_CD
products_NN
and_CC
new_JJ
treatments_NOMZ
in_PIN
other_JJ
Diprivan_NN
500_CD
458_CD
5_CD
million_CD
of_PIN
Diprivan_JJ
sales_NN
._.
areas_NN
of_PIN
inflammatory_JJ
disease_NN
,_,
such_JJ
as_IN
Zomig_NN
356_CD
349_CD
3_CD
chronic_NN
obstructive_JJ
pulmonary_JJ
disease_NN
Local_JJ
anaesthetics_NN
542_CD
466_CD
8_CD
Oncology_NN
COPD_NN
and_CC
rheumatoid_JJ
arthritis_NN
._.
Other_JJ
71_CD
73_CD
10_CD
We_FPP1
aim_VPRT
to_TO
maintain_VB [PUBV]
our_FPP1
position_NOMZ
as_IN
a_DT
Total_JJ
3,496_CD
2,833_CD
19_CD
world_NN
leader_NN
in_PIN
cancer_NN
treatment_NOMZ
through_PIN
The_DT
World_NN
Health_NN
Organization_NOMZ
estimates_VPRT [PRIV]
further_JJ
launches_NN
for_PIN
our_FPP1
new_JJ
products_NN
,_,
that_THVC
100_CD
million_CD
people_NN
worldwide_JJ
suffer_VPRT
Key_NN
product_NN
sales_NN
:_:
Oncology_NN
the_DT
successful_JJ
introduction_NOMZ
of_PIN
novel_NN
from_PIN
asthma_NN
and_CC
that_THVC
COPD_NN
is_VPRT [BEMA]
the_DT
fourth_JJ
2004_CD
2003_CD
Underlying_JJ
approaches_NN
currently_RB
in_PIN
the_DT
pipeline_NN
and_CC
greatest_JJ
cause_NN
of_PIN
death_NN
worldwide_NN
._.
$_$
m_CD
$_$
m_JJ
growth_NN
%_NN
the_DT
continued_JJ
growth_NN
of_PIN
key_JJ
products_NN
Casodex_NN
1,012_CD
854_CD
11_CD
in_PIN
our_FPP1
portfolio_NN
._.
Clinical_JJ
data_NN
confirm_VPRT [PUBV]
the_DT
efficacy_NN
and_PHC
safety_NN
Zoladex_NN
917_CD
869_CD
1_CD
of_PIN
Symbicort_NN
as_IN
an_DT
adjustable_JJ
maintenance_NN
Arimidex_NN
811_CD
519_CD
48_CD
Six_CD
million_CD
people_NN
die_VPRT
from_PIN
cancer_NN
every_QUAN
treatment_NOMZ
for_PIN
asthma_NN
,_,
providing_VBG
superior_JJ
Iressa_NN
389_CD
228_CD
65_CD
year_NN
representing_VBG [WZPRES]
12_CD
%_NN
of_PIN
deaths_NN
worldwide_VPRT
._.
asthma_NN
control_NN
compared_VBN [WZPAST]
to_PIN
traditional_JJ
Nolvadex_NN
134_CD
178_CD
31_CD
Symbicort_NN
fixed_VBN
dose_NN
treatment_NOMZ
._.
During_PIN
Faslodex_NN
99_CD
77_CD
28_CD
Iressa_NN
,_,
used_VBN [PASTP]
for_PIN
the_DT
treatment_NOMZ
of_PIN
non-small_JJ
the_DT
year_NN
,_,
we_FPP1
withdrew_VBD
our_FPP1
regulatory_JJ
Other_JJ
14_CD
18_CD
28_CD
cell_NN
lung_NN
cancer_NN
,_,
is_VPRT [BEMA]
a_DT
highly_AMP
researched_VBN
submission_NN
in_PIN
Europe_NN
for_PIN
Symbicort_NN
single_JJ
Total_JJ
3,376_CD
2,743_CD
16_CD
anti-cancer_JJ
agent_NN
that_TSUB
acts_VPRT
to_TO
block_VB
signals_NN
inhaler_JJ
therapy_NN
SiT_NN
._.
We_FPP1
aim_VPRT
to_TO
submit_VB [PUBV]
a_DT
for_PIN
cancer_NN
cell_NN
growth_NN
and_PHC
survival_NN
._.
regulatory_JJ
filing_NN
in_PIN
the_DT
second_JJ
half_NN
of_PIN
2005_CD
Key_NN
product_NN
sales_NN
:_:
However_CONJ
,_,
in_PIN
December_NN
2004_CD
initial_JJ
results_NN
for_PIN
Symbicort_NN
SiT_NN
containing_VBG [WZPRES]
additional_JJ
Respiratory_NN
&_CC
Inflammation_NOMZ
from_PIN
the_DT
recent_JJ
ISEL_NN
study_NN
showed_VBD [PRIV]
that_THVC
data_NN
from_PIN
further_JJ
ongoing_JJ
studies_NN
._.
A_DT
2004_CD
2003_CD
Underlying_JJ
$_$
m_CD
$_$
m_JJ
growth_NN
%_NN
statistically_RB
,_,
Iressa_NN
did_VBD
not_XX0
significantly_RB
regulatory_JJ
application_NOMZ
for_PIN
approval_NN
in_PIN
Pulmicort_NN
1,050_CD
968_CD
4_CD
increase_NN
survival_NN
of_PIN
the_DT
overall_JJ
population_NOMZ
._.
Europe_NN
of_PIN
Symbicort_NN
pressurized_VBD
metered_VBN
Symbicort_NN
797_CD
549_CD
32_CD
Data_NN
suggest_VPRT [SUAV] [PUBV]
survival_NN
benefits_NN
in_PIN
patient_JJ
dose_NN
inhaler_NN
for_PIN
use_NN
in_PIN
asthma_NN
and_CC
in_PIN
Rhinocort_NN
361_CD
364_CD
3_CD
populations_NOMZ
of_PIN
East_PLACE
Asian_JJ
origin_NN
and_CC
in_PIN
COPD_NN
was_VBD [PASS]
made_VBN
in_PIN
July_NN
2004_CD
._.
Iressa_NN
is_VPRT [PASS]
approved_VBN
in_PIN
35_CD
Oxis_NN
101_CD
120_CD
24_CD
countries_NN
including_VBG [WZPRES]
the_DT
US_FPP1
and_PHC
Japan_NN
._.
In_PIN
the_DT
US_FPP1
,_,
sales_NN
of_PIN
Pulmicort_NN
Respules_NN
Other_JJ
158_CD
153_CD
5_CD
We_FPP1
are_VPRT [BEMA]
now_TIME
in_PIN
consultation_NOMZ
with_PIN
regulatory_JJ
continue_VPRT
to_TO
grow_VB
,_,
further_JJ
strengthening_VBG
its_PIT
Total_JJ
2,583_CD
2,261_CD
8_CD
authorities_NOMZ
to_TO
determine_VB [SUAV] [PRIV]
the_DT
impact_NN
of_PIN
the_DT
position_NOMZ
as_IN
the_DT
inhaled_JJ
corticosteroid_NN
of_PIN
ISEL_NN
data_NN
._.
We_FPP1
have_VPRT [PEAS]
withdrawn_VBN
the_DT
choice_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
children_NN
under_IN
n_NN
m_NN [BEMA]
not_XX0
meaningful_JJ
European_JJ
Marketing_GER
Authorisation_NOMZ
five_CD
with_PIN
asthma_NN
._.
Application_NOMZ
and_CC
voluntarily_RB
suspended_VBN
promotion_NOMZ
of_PIN
Iressa_NN
in_PIN
the_DT
US_FPP1
._.
We_FPP1
intend_VPRT [SUAV]
however_CONJ [WHCL]
to_TO
continue_VB
to_TO
make_VB
Iressa_NN
available_JJ
for_PIN
patients_NN
whose_WPS [WHOBJ]
physicians_NN
feel_VPRT [PRIV] [THATD]
they_TPP3
are_VPRT
benefiting_VBG
from_PIN
the_DT
drug_NN
._.
